Skip to main content


Fig. 3 | Cancer Communications

Fig. 3

From: Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety

Fig. 3

The subgroup analysis of the a disease-free survival (DFS) and b overall survival (OS) of enrolled patients who underwent radical hepatectomy only compared to those who had radical hepatectomy and adjuvant TACE. HR: hazard ratio; CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance score. Survival data are presented as median with 95% CI in parentheses

Back to article page